Urinary protein profiling by liquid chromatography/tandem mass spectrometry: ADAM28 is overexpressed in bladder transitional cell carcinoma

Rapid Communications in Mass Spectrometry

Volumn 25, Issue 19, 2011, Pages 2851-2862

  Tyan, Yu Chang ^a,b   Yang, Ming Hui ^c   Chen, Sharon Chia Ju ^a   Jong, Shiang Bin ^a   Chen, Wen Cheng ^d   Yang, Yuan Han ^e   Chung, Tze Wen ^c   Liao, Pao Chi ^f  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^c NATIONAL YUNLIN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^d FENG CHIA UNIVERSITY   (China)

^e KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PEPTIDES;

BLACKFOOT DISEASE; BLADDER CANCERS; CONTROL GROUPS; HIGH INCIDENCE; INCIDENCE RATE; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY; PROTEIN PROFILING; TRANSITIONAL CELL CARCINOMA; URINARY PROTEINS;

MASS SPECTROMETRY;

EID: 80052597041     PISSN: 09514198     EISSN: 10970231     Source Type: Journal    
DOI: 10.1002/rcm.5169     Document Type: Conference Paper

References (63)

1. J. E. Celis, I. Gromova, J. M. A. Moreira, T. Cabezón, P. Gromov. Impact of proteomics on bladder cancer research. Pharmacogenomics 2004, 5, 381.
2. B. L. Bane, J. Y. Rao, G. P. Hemstreet. Pathology and staging of bladder cancer. Semin. Oncol. 1996, 23, 549.
3. J. P. Tolson, T. Flad, V. Gnau, H. Dihazi, J. Hennenlotter, A. Beck, G. A. Mueller, M. Kuczyk, C. A. Mueller. Differential detection of S100A8 in transitional cell carcinoma of the bladder by pair wise tissue proteomic and immunohistochemical analysis. Proteomics 2006, 6, 697.
4. H. Y. Chiou, S. T. Chiou, Y. H. Hsu, Y. L. Chou, C. H. Tseng, M. L. Wei, C. J. Chen. Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8, 102 residents in an arseniasis-endemic area in northeastern Ta i w a n. Am. J. Epidemiol. 2001, 153, 411.
5. L. E. Moore, A. H. Smith, C. Eng, D. Kalman, S. DeVries, V. Bhargava, K. Chew, D. Moore, C. Ferreccio, O. A. Rey, F. M. Waldman. Arsenic-related chromosomal alterations in bladder cancer. J. Natl. Cancer Inst. 2002, 94, 1688.
6. K. P. Cantor. Drinking water and cancer. Cancer Control 1997, 8, 292.
7. J. Liu, Y. Xie, J. M. Ward, B. A. Diwan, M. P. Waalkes. Toxicogenomic analysis of aberrant gene expression in liver tumors and nontumorous livers of adult mice exposed in utero to inorganic arsenic. Toxicol. Sci. 2004, 77, 249.
8. National Research Council (NRC). Arsenic in the drinking water. National Academy Press, Washington, 1999.
9. C. Y. Yang, H. F. Chiu, C. C. Chang, S. C. Ho, T. N. Wu. Bladder cancer mortality reduction after installation of a tap-water supply system in an arsenious-endemic area in southwestern Taiwan. Environ. Res. 2005, 98, 127.
10. H. Y. Chiou, Y. M. Hsueh, K. F. Liaw, S. F. Horng, M. H. Chiang, Y. S. Pu, J. S. Lin, C. H. Huang, C. J. Chen. Incidence of internal cancers and ingested inorganic arsenic: a seven-year follow-up study in Taiwan. Cancer Res. 1995, 55, 1296.
11. T. Tsuda, A. Babazono, E. Yamamoto, N. Kurumatani, Y. Mino, T. Ogawa, Y. Kishi, H. Aoyama. Ingested arsenic and internal cancer: a historical cohort study followed for 33 years. Am. J. Epidemiol. 1995, 141, 198.
12. C. Hopenhayn-Rich, M. L. Biggs, A. Fuchs. Bladder cancer mortality associated with arsenic in drinking water in Argentina. Epidemiology 1996, 7, 117.
13. A. H. Smith, M. Goycolea, R. Haque, M. L. Biggs. Marked increase in bladder and lung cancer mortality in a region of northern Chile due to arsenic in drinking water. Am. J. Epidemiol. 1998, 147, 660.
14. B. R. Konety, R. D. Williams. Superficial transitional (Ta/T1/CIS) cell carcinoma of the bladder. BJU Int. 2004, 94, 18.
15. H. B. Grossman. New methods for detection of bladder cancer. Semin. Urol. Oncol. 1998, 16, 17.
16. S. Ramakumar, J. Bhuiyan, J. A. Besse, S. G. Roberts, P. C. Wollan, M. L. Blute, D. J. O'Kane. Comparison of screening methods in the detection of bladder cancer. J. Urol. 1999, 161, 388.
17. Y. F. Zhang, D. L. Wu, M. Guan, W. W. Liu, Z. Wu, Y. M. Chen, W. Z. Zhang, Y. Lu. Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient. Clin. Biochem. 2004, 37, 772.
18. H. Lwaki, S. Kageyama, T. Isono, Y. Wajabayashi, Y. Okada, K. Yoshimura, A. Terai, Y. Arai, H. Iwamura, M. Kawakita, T. Yoshiki. Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gamma-synuclein, and catechol-o-methyltransferase) identified by proteomic analysis. Cancer Sci. 2004, 95, 955.
19. S. Kageyama, T. Isono, H. Iwaki, Y. Wajabayashi, Y. Okada, K. Kontani, K. Yoshimura, A. Terai, Y. Arai, T. Yoshiki. Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin. Chem. 2004, 50, 857.
20. J. E. Celis, P. Celis, H. Palsdottir, M. Østergaard, P. Gromov, H. Primdahi, T. F. Ørntoft, H. Wolf, A. Celis, I. Gromova. Proteomic strategies to reveal tumor heterogeneity among urothelial papillomas. Mol. Cell. Proteomics 2002, 1, 269.
21. S. W. Lee, K. I. Lee, J. Y. Kim. Revealing urologic diseases by proteomic techniques. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.. 2005, 815, 203.
22. M. Saito, M. Kimoto, T. Araki, Y. Shimada, R. Fujii, K. Oofusa, M. Hide, T. Usui, K. Yoshizato. Proteome analysis of gelatin-bound urinary proteins from patients with bladder cancers. Eur. Urol. 2005, 48, 865.
23. D. J. Hampel, C. Sansome, M. Sha, S. Brodsky, W. E. Lawson, M. S. Goligorsky Toward proteomics in uroscopy: urinary protein profiles after radiocontrast medium administration. J. Am. Soc. Nephrol. 2001, 12, 1026.
24. M. Jürgens, A. Appel, G. Heine, S. Neitz, C. Menzel, H. Tammen, H. D. Zucht. Towards characterization of the human urinary peptidome. Comb. Chem. High Throughput Screen. 2005, 8, 757.
25. R. Pieper, C. L. Gatlin, A. M. McGrath, A. J. Makusky, M. Mondal, M. Seonarain, E. Field, C. R. Schatz, M. A. Estock, N. Ahmed, N. G. Anderson, S. Steiner. Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on twodimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics 2004, 4, 1159.
26. M. M. Bradford. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248.
27. Y. C. Tyan, H. Y. Wu, W. W. Lai, W. C. Su, P. C. Liao. Proteomic profiling of human pleural effusion using two-dimensional nano liquid chromatography tandem mass spectrometry. J. Proteome Res. 2005, 4, 1274.
28. Available: ftp.ncbi.bih.gov/blast.db.
29. Y. C. Tyan, H. Y. Wu, W. C. Su, P. W. Chen, P. C. Liao. Proteomic analysis of human pleural effusion. Proteomics 2005, 5, 1062.
30. NCBI PubMed. Available: http://www.ncbi.nlm.nih.gov/.
31. SWISS-Prot/TrEMBL. Available: http://www.expasy.org/.
32. Bioinformatic Harvester EMBL. Available: http://harvester.embl.de/.
33. X. C. Le, X. Lu, M. Ma, W. R. Cullen, H. V. Aposhian, B. Zheng, Speciation of key arsenic metabolic intermediates in human urine. Anal. Chem. 2000, 72, 5172.
34. C. K. Jain, I. Ali. Arsenic: occurrence, toxicity and speciation techniques. Water Res. 2000, 34, 4304.
35. X. J. Li, H. Zhang, J. A. Ranish, R. Aebersold. Automated statistical analysis of protein abundance ratios from data generated by stable-isotope dilution and tandem mass spectrometry. Anal. Chem. 2003, 75, 6648.
36. C. C. Chao, D. Chelius, T. Zhang, L. Daggle, W. M. Ching, Proteome analysis of Madrid E strain of Rickettsia prowazekii. Proteomics 2004, 4, 1280.
37. R. Xiang, Y. Shi, D. A. Dillon, B. Negin, C. Horváth, J. A. Wilkins. 2D LC/MS analysis of membrane proteins from breast cancer cell lines MCF7 and BT474. J. Proteome Res. 2004, 3, 1278.
38. J. D. Jaffe, H. C. Berg, G. M. Church. Proteogenomic mapping as a complementary method to perform genome annotation. Proteomics 2004, 4, 59.
39. V. Thongboonkerd, K. R. McLeish, J. M. Arthur, J. B. Klein. Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int. 2002, 62, 1461.
40. C. S. Spahr, M. T. Davis, M. D. McGinley, J. H. Robinson, E. J. Bures, J. Beierle, J. Mort, P. L. Courchesne, K. Chen, R. C. Wahl, W. Yu, R. Luethy, S. D. Patterson. Towards defining the urinary proteome using liquid chromatography-tandem mass spectrometry. I. Profiling an unfractionated tryptic digest. Proteomics 2001, 1, 93.
41. J. Oh, J. H. Pyo, E. H. Jo, S. I. Hwang, S. C. Kang, J. H. Jung, E. K. Park, S. Y. Kin, J. Y. Choi, J. Lim. Establishment of a near-standard two-dimensional human urine proteomic map. Proteomics 2004, 4, 3485.
42. A. Castagna, D. Cecconi, L. Sennels, J. Rappsilber, L. Guerrier, F. Fortis, E. Boschetti, L. Lomas, P. G. Righetti. Exploring the hidden human urinary proteome via ligand library beads. J. Proteome Res. 2005, 4, 1917.
43. J. X. Pang, N. Ginanni, A. R. Dongre, S. A. Hefta, G. J. Opiteck. Biomarker discovery in urine by proteomics. J. Proteome Res. 2002, 1, 161.
44. S. S. Hong, S. W. Kwon. Profiling of urinary proteins by nano-high performance liquid chromatography/tandem mass spectrometry. J. Liq. Chromatogr. Rel. Technol. 2005, 28, 805.
45. G. Heine, M. Raida, W. G. Forssmann. Mapping of peptides and protein fragments in human urine using liquid chromatography-mass spectrometry. J. Chromatogr. A 1997, 776, 117.
46. M. R. Park, E. H. Wang, D. C. Jin, J. H. Cha, K. H. Lee, C. W. Yang, C. S. Kang, Y. J. Choi. Establishment of a 2-D human urinary proteomic map in IgA nephropathy. Proteomics 2006, 6, 1066.
47. Q. C. Ru, R. A. Katenhusen, L. A. Zhu, J. Silberman, S. Yang, T. J. Orchard, H. Brzeski, M. Liebman, D. L. Ellsworth. Proteomic profiling of human urine using multi-dimensional protein identification technology. J. Chromatogr. A 2006, 14, 166.
48. G. Smith, D. Barratt, R. Rowlinson, J. Nickson, R. Tonge. Development of a high-throughput method for preparing human urine for two-dimensional electrophoresis. Proteomics 2005, 5, 2315.
49. C. Y. Chen, J. H. Jia, M. X. Zhang, Y. B. Zhou, R. M. Zhang, X. P. Yu. Comparative proteomics of apoptosis initiation induced by 5-fluorouracil in human gastric cancer. Chinese J. Physiol. 2006, 49, 31.
50. C. A. Borgoño, E. P. Diamandis. The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer 2004, 4, 876.
51. J. Lu, K. M. Goldstein, P. Chen, S. Huang, L. M. Gelbert, S. Nagpal. Transcriptional profiling of keratinocytes reveals a vitamin D-regulated epidermal differentiation network. J. Invest. Dermatol. 2005, 124, 778.
52. N. Devoogdt, G. G. Hassanzabeh, J. Zhang, L. Brys, P. De Bartselier, H. Revets. Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc. Natl. Acad. Sci. 2003, 100, 5778.
53. M. Kabesch, D. Carr, S. K. Weiland, E. von Mutius. Association between polymorphisms in serine protease inhibitor, kazal type 5 and asthma phenotypes in a large German population sample. Clin. Exp. Allergy 2004, 34, 340.
54. E. E. Bates, W. H. Fridman, C. G. Mueller. The ADAMDEC1 (decysin) gene structure: evolution by duplication in a metalloprotease gene cluster on chromosome 8p12. Immunogenetics 2002, 54, 96.
55. S. Mochizuki, Y. Okada. ADAMs in cancer cell proliferation and progression. Cancer Sci. 2007, 5, 621.
56. Y. Okada. Modulation of the microenvironment and adhesion of cancer cells by ADAMs (a disintegrin and metalloproteinase). Verh. Dtsch. Ges. Pathol. 2007, 91, 29.
57. H. Kuroda, S. Mochizuki, M. Shimoda, M. Chijiiwa, K. Kamiya, Y. Izumi, M. Watanabe, H. Horinouchi, M. Jawamura, K. Kobyashi, Y. Okada. ADAM28 is a serological and histochemical marker for non-small-cell lung cancers. Int. J. Cancer 2010, 127, 1844.
58. Y. Mitsui, S. Mochizuki, T. Kodama, M. Shimoda, T. Ohtsuka, T. Shiomi, M. Chijiiwa, T. Ikeda, M. Kitajima, Y. Okada. ADAM28 is overexpressed in human breast carcinomas: implications for carcinoma cell proliferation through cleavage of insulin-like growth factor binding protein-3. Cancer Res. 2006, 66, 9913.
59. C. Wu, L. Zhang, P. A. Bourne, J. E. Reeder, P. A. di Sant'Agnese, J. L. Yao, Y. Na, J. Huang. Protein tyrosine phosphatase PTP1B is involved in neuroendocrine differentiation of prostate cancer. Prostate 2006, 66, 1125.
60. H. Charbonneau, N. K. Tonks, S. Kumar, C. D. Diltz, M. Harrylock, D. E. Cool, E. G. Krebs, E. H. Fischer, K. A. Walsh. Human placenta protein-tyrosine-phosphatase: amino acid sequence and relationship to a family of receptorlike proteins. Proc. Nat. Acad. Sci. 1989, 86, 5252.
61. C. O'Donovan, M. J. Martin, A. Gattiker, E. Gasteiger, A. Bairoch, R. Apweiler. High-quality protein knowledge resource: SWISS-PROT and TrEMBL. Brief. Bioinform. 2002, 3, 275.
62. Y. Guo, S. F. Ma, D. Grigoryev, J. Van Eyk, J. G. Garcia. 1-DE MS and 2-D LC-MS analysis of the mouse bronchoalveolar lavage proteome. Proteomics 2005, 5, 4608.
63. Available: http://us.expasy.org/ch2d/publi/inside1995.